Growth & Strategy - Digital Realty targets mid-single-digit Core FFO growth in 2026+ [9] - Digital Realty launched a US Hyperscale Data Center Fund targeting approximately $2.5 billion of LP capital commitments [24] - The US Hyperscale Data Center Fund has received subscriptions for commitments to date of over $800 million from institutional investors [31] Financial Performance & Position - Digital Realty's Net Debt to Adjusted EBITDA was 4.8x as of 4Q24 [14, 15, 40] - Digital Realty's equity market capitalization was $61 billion as of December 31, 2024 [17, 35] - Digital Realty's liquidity was $6 billion at the end of 2024 [17, 40] - Total 2024 bookings exceeded $1 billion [40, 79, 83] - Total 2024 renewals reached $970 million [40, 79] Portfolio & Capacity - Digital Realty has over 300 data centers [35, 79] - Digital Realty's global capacity is approximately 2,700 MW [44] - Digital Realty has over 3,500 MW of future development capacity [47] Customer Base & Connectivity - Digital Realty has over 5,000 customers [35, 79, 102] - Digital Realty has over 227,000 cross connects [35, 65, 79]

Safe-Harbor Statement This presentation contains forward-looking statements that are subject to risks and uncertainties, and which reflect management's current beliefs and estimates of future economic circumstances, industry conditions, Company performance, financial results and planned financing. You can find a discussion of many of these risks and uncertainties in the annual, quarterly and current reports that the Company files with the Securities and Exchange Commission. Investors should understand that ...

Cretostimogene Clinical Development and Efficacy - CG Oncology's clinical development strategy targets approximately 70% of the Non-Muscle Invasive Bladder Cancer (NMIBC) market, representing a multi-billion dollar opportunity[10, 49] - In a Phase 3 registrational study for High-Risk BCG-unresponsive NMIBC, cretostimogene demonstrated a potential best-in-class efficacy with a 75% Complete Response (CR) rate at any time[10] - The 12-month Duration of Response (DoR) was 63.5%, and the 24-month DoR was 56.6%, with the median DoR exceeding 27 months and ongoing in the Phase 3 study[10] - In the BOND-003 Cohort C trial, 97.3% of patients were free from progression to MIBC at 12 months[23] - Cystectomy-Free Survival in BOND-003 Cohort C was 90% at 12 months[23] - In BOND-003 Cohort C, 50% of patients reinduced with oncolytic immunotherapy converted to CR, and 64.3% remained in durable response after conversion[28] Safety and Tolerability - Cretostimogene has a favorable safety profile with 0% Grade 3 or higher treatment-related adverse events observed in clinical trials[10, 30] - In the cretostimogene arm, 64.3% of patients experienced any grade of Treatment-Related Adverse Events (TRAEs)[31] Financial and Strategic Outlook - CG Oncology has a strong balance sheet with a cash runway expected into the first half of 2028 to drive commercialization and indication expansion[10] Market and Treatment Landscape - Physicians in top key accounts treat more than 70% of NMIBC patients by volume[46]

Efficacy Highlights - Pemvidutide demonstrated statistically significant MASH resolution without worsening of fibrosis, reaching up to 59.1% at 24 weeks[55] - Fibrosis improvement without worsening of MASH was observed in up to 34.5% of patients at 24 weeks[55] - Liver fat content was reduced by up to 62.8%[55] - Patients experienced weight loss of up to 6.2% which continued through 24 weeks without plateauing[55] Safety and Tolerability - The trial showed potentially best-in-class tolerability with a low discontinuation rate of less than 1% due to adverse events in subjects receiving pemvidutide[55] - There were no heart rate increases or differences in cardiac adverse events between the pemvidutide and placebo groups[55] Additional Benefits - Pemvidutide maintained HbA1c levels regardless of diabetes status[55] - The trial observed statistically significant improvements in non-invasive tests of fibrosis[55] - Alanine Aminotransferase (ALT) was significantly reduced in ITT Analysis, with reductions of -34.4 IU/L in the 1.2 mg group and -34.6 IU/L in the 1.8 mg group compared to -10.0 IU/L in the placebo group[40]

2025 Sonoco Annual Meeting of Shareholders BOARD OF DIRECTORS Steven Boyd Scott Clark Howard Coker Pamela Davies Theresa Drew Philippe Guillemot 2 BOARD OF DIRECTORS John Haley Robert Hill Eleni Istavridis Richard Kyle Blythe McGarvie Thomas Whiddon 3 2025 Annual Meeting Items of Business Proposal 1 Election of Directors Proposal 2 Ratification of Independent Registered Public Accounting Firm Proposal 3 Advisory (Non-binding) Vote on Executive Compensation Proposal 4 5 State of Sonoco Howard Coker President ...

Actual results could differ materially from those projected in the forward-looking statements. The Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. Business Update, Financial Results, and Outlook 2nd Quarter 2025 2 2nd Quarter 2025 McCormick & Company, Inc. Business Update, Financial Results, and Outlook | June 26, 2025 The following slides accompany a June 26, 2 ...

Cretostimogene Clinical Programs & Efficacy - Cretostimogene targets over 70% of the Non-Muscle Invasive Bladder Cancer (NMIBC) market[10] - In High-Risk BCG-Unresponsive NMIBC CIS, Cretostimogene monotherapy (BOND-003 Cohort C) achieved a 12-month Complete Response (CR) rate of 46.4% (51 out of 110 patients) and an estimated 24-month CR rate of 42.3%[30] - In High-Risk BCG-Unresponsive NMIBC Ta/T1 (BOND-003 Cohort P), Cretostimogene demonstrates a 90.5% High Grade Recurrence-Free Survival (HG-RFS) rate at 3, 6, and 9 months[16, 54] - In CORE-008 CX (Cretostimogene in combination with gemcitabine), the Overall Complete Response was 75%[61] Safety & Durability - Cretostimogene demonstrates best-in-disease durability data, with a median Duration of Response (DoR) exceeding 28 months and ongoing in HR BCG-UR NMIBC[12, 38] - 97.3% of patients treated with Cretostimogene were free from progression to MIBC at 24 months[14, 32] - 91.6% of responders avoided radical cystectomy by month 24[14, 32] - Cretostimogene has a favorable safety profile, with 0% Grade ≥ 3 treatment-related Adverse Events (AEs) reported[12, 43, 45] Trial Updates & Market Position - The Phase 3 trial of adjuvant Cretostimogene for Intermediate Risk NMIBC (PIVOT-006) is expected to fully enroll ahead of schedule in 2H'25[15, 55] - Cretostimogene is positioned as a backbone therapy in NMIBC, with ease of delivery and administration for patients, physicians, and practice providers[12, 50]

Leader in AI-Driven Energy Solutions January 2022 1 Cautionary Statement Regarding Forward-Looking Statements This presentation, as well as other statements we make, contains "forward-looking statements" within the meaning of the federal securities laws, which include any statements that are not historical facts. Such statements often contain words such as "expect," "may," "can," "believe," "predict," "plan," "potential," "projected," "projections," "forecast," "estimate," "intend," "anticipate," "ambition, ...

September 2023 Investor Presentation Cautionary Statement Regarding Forward-Looking Statements This presentation, as well as other statements we make, contains "forward-looking statements" within the meaning of the federal securities laws, which include any statements that are not historical facts. Such statements often contain words such as "expect," "may," "can," "believe," "predict," "plan," "potential," "projected," "projections," "forecast," "estimate," "intend," "anticipate," "ambition," "goal," "targ ...

Company Overview - Singular Genomics has raised approximately $450 million [10] - The company held $133 million in cash as of June 30, 2024 [10] - The company has approximately 195 employees [12] - The company has around 300 issued and pending patents [10, 12] Market Opportunity - The Next Generation Sequencing market is estimated at $7 billion in 2023, projected to reach $20 billion by 2030 [17] - The Spatial Sequencing market is estimated at $2 billion in 2023, projected to reach $11 billion by 2030, representing a 23% CAGR [19, 46] G4 Platform - The G4 platform offers flexibility with 1-4 flow cells and 16 lanes [28] - The G4 platform can achieve run times of 8-24 hours [28] - The G4 platform can produce up to 480 Gb output [28] G4X Platform - The G4X platform has a 40 cm² imaging area [77, 82] - The G4X platform offers high-throughput spatial sequencing with multiomic capabilities, including RNA, protein, and H&E [82]